Explore
Validate
Learn
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA1-9553 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- SLC19A1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Purifed from natural sources
- Description
- PA1-9553 detects SLC19A1 in human samples.
- Concentration
- 1 mg/mL
Submitted references Paradoxical impact of two folate receptors, FRĪ± and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome.
Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, Ngan HY, Le XF, Cheung AN
PloS one 2012;7(11):e47201
PloS one 2012;7(11):e47201
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Down-regulation of RFC in ovarian cancers and correlation with prognosis of patients. (A) qPCR analysis of RFC mRNA in ovarian tumors and the corresponding non-tumor counterparts. (B) mRNA (upper panel) and protein (lower panel) expression of RFC in two immortalized ovarian epithelial cell lines, HOSE 6-3 and HOSE-17-1, and nine ovarian cancer cell lines, SKOV-3, OVCAR-3, OVCA 420, OVCA433, OC316, Dov13, ES-2, TOV21G, SW626, as assessed by qPCR and immunoblotting respectively. (C) Immunoreactivity of RFCin inclusion cyst (a) and serous ovarian carcinomas (b). Scale bar = 100 um. (D) Kaplan-Meier overall (left panel) and disease-free (right panel) survival curves for ovarian cancer patients with high and low levels of RFC (cut off at mean). (E) Kaplan-Meier overall (left panel) and disease-free (right panel) survival curves for high FRalpha expressed ovarian cancer patients with high and low levels of RFC (cut off at mean).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Ectopic overexpression of RFC in FRalpha-positive SKOV-3 counteracted folate-mediated cell proliferation, migration and invasion, and down-regulation of E-cadherin. (A) Cell proliferation rate of SKOV-3 cells with ectopically expressed RFC or control vector (control) treated with 60 nM folate after 5 days displayed as fold change compared to control without folate treatment (0 nM); n = 3; *, P
